🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

biorxiv.org/content/10.110…

Here is a newly published article about Atxn1 and Alzheimer. authors.elsevier.com/c/1Zc2xL7PXYW6M

While not brain cancer, this is a nice paper investigating the link between nonsense mediated decay, inflammation and neurodevelopmental disorders. cell.com/neuron/fulltex…

Akdes points out a true limitation of sharing genomic data and privacy concerns. Finding a true solution is so important. Great work Akdes.

I’m proud to announce the publication of our research in PNAS. Meningioma, it’s causes and better diagnosis is important. Spread the word and support our research! pnas.org/content/early/….

I hope our new study will facilitate a better understanding in modeling Meningioma in vitro and in vivo. It’s of importance to note, how resilient meningiomas are to growth outside its original cancer micro environment. (mdpi.com/2072-6694/12/6…)

As promised, 2/2/22 and its 2pm EST. Proud of the work that our team was able to accomplish using multi-platform profiling of meningiomas. Check it out in Science Advances: science.org/doi/10.1126/sc… Tiemo J. Klisch Arif Ozgun Harmanci Akdes Serin Harmanci From the Labs at Baylor College of Medicine BCM Neurosurgery

Studying meningiomas from our patients, our residents Drs. Jim Bayley and Caroline Hadley worked with Akash Patel Tiemo J. Klisch Akdes Serin Harmanci Arif Ozgun Harmanci to move the needle on understanding meningiomas. Read about it in Science Advances. NIHBrainTumor science.org/doi/10.1126/sc…

We are so happy to have collaborated with top Meningioma researcher in the world. We believe the field is closer than ever to get to a consensus on MenG subtyping. This will leap the field forward to help all current and future patients. science.org/doi/10.1126/sc…

Homozygous Sahm Lab AND heterozygous CDKN2A loss in meningioma portend poor prognosis. Step 1: look for group C/hypermitotic meningiomas (half recur by 47 months) Step2: further refine prognosis with CDKN2A/B status.Tiemo J. Klisch BCMHouston RaleighLab link.springer.com/article/10.100…

Congrats to all authors! MenGC Meningioma Are the real threat and should be included into the WHO grading system! At the very least CDKN2A/B het loss must be be added! urldefense.proofpoint.com/v2/url?u=https…

Thank you all for the hard work. It’s amazing how similar dog and human meningioma are. texaschildrens.org/content/resear…

After the publication yesterday, I am glad that Dr Patel was awarded a CPRIT grant to further study meningioma finding new treatments for his patients. Proud to work with him & his team! Akash Patel BCM Neurosurgery CPRIT Texas Children's Arif Ozgun Harmanci Akdes Serin Harmanci

I'm lucky to have an amazing team Tiemo J. Klisch Akdes Serin Harmanci Arif Ozgun Harmanci of collaborators here in Houston and at the Jan and Dan Duncan Neurological Research Institute. Looking forward to carrying on the work, thanks to CPRIT!